Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
08/18/2023 | AN2 Therapeutics, Inc. | | Purchase | Common Stock | 1.8M | $9.00 | $16M | See Footnotes | 08/18/2023 |
08/09/2023 | DICE Therapeutics, Inc. | DICE | Other | Common Stock | 7.1M | $0.00 | $0 | See Footnotes | 08/09/2023 |
08/09/2023 | DICE Therapeutics, Inc. | DICE | Other | Common Stock | 786.4k | $0.00 | $0 | See Footnotes | 08/09/2023 |
08/09/2023 | DICE Therapeutics, Inc. | DICE | Disposition | Stock Option (Right to Buy) | 21.2k | $14.98 | $318.3k | See Footnotes | 08/09/2023 |
08/07/2023 | Wave Life Sciences Ltd. | WVE | Grant | Share Option (Right to Buy) | 45k | $4.58 | $206.1k | See Footnotes | 08/07/2023 |
07/05/2023 | Black Diamond Therapeutics, Inc. | BDTX | Purchase | Common Stock | 935.8k | $5.00 | $4.7M | See Footnotes | 07/05/2023 |
06/27/2023 | ARS Pharmaceuticals, Inc. | SBTX | Grant | Stock Option (Right to Buy) | 40k | $6.50 | $260k | See footnotes | 06/27/2023 |
06/14/2023 | Janux Therapeutics, Inc. | | Grant | Stock Option (Right to Buy) | 12.5k | $13.22 | $165.2k | See footnotes | 06/14/2023 |
06/08/2023 | Satsuma Pharmaceuticals, Inc. | STSA | Disposition | Stock Option (Right to Buy) | 20k | $4.60 | $92k | See Footnotes | 06/08/2023 |
06/08/2023 | Satsuma Pharmaceuticals, Inc. | STSA | Disposition | Stock Option (Right to Buy) | 30k | $3.46 | $103.8k | See Footnotes | 06/08/2023 |
06/08/2023 | Satsuma Pharmaceuticals, Inc. | STSA | Disposition | Stock Option (Right to Buy) | 10k | $26.99 | $269.9k | See Footnotes | 06/08/2023 |
06/08/2023 | Satsuma Pharmaceuticals, Inc. | STSA | Other | Common Stock | 5.9M | $0.00 | $0 | See Footnotes | 06/08/2023 |
06/07/2023 | Nkarta, Inc. | NKTX | Grant | Stock Option (Right to Buy) | 22.5k | $4.86 | $109.4k | See Footnotes | 06/07/2023 |
06/06/2023 | Aerovate Therapeutics, Inc. | AVTE | Grant | Stock Option (Right to Buy) | 12.5k | $16.30 | $203.8k | See Footnotes | 06/06/2023 |
06/06/2023 | Solid Biosciences Inc. | SLDB | Grant | Director Stock Option (Right to Buy) | 9.6k | $6.37 | $61.5k | See Footnotes | 06/06/2023 |
06/06/2023 | Icosavax, Inc. | ICVX | Grant | Stock Option (Right to Buy) | 17k | $9.89 | $168.1k | See Footnotes | 06/06/2023 |
05/31/2023 | Tyra Biosciences, Inc. | | Grant | Stock Option (Right to Buy) | 14.5k | $14.47 | $209.8k | See Footnotes | 05/31/2023 |
05/26/2023 | Vor Biopharma Inc. | | Grant | Stock Option (Right to Buy) | 30k | $4.79 | $143.7k | See Footnotes | 05/26/2023 |
03/27/2023 | DICE Therapeutics, Inc. | DICE | Purchase | Common Stock | 151.1k | $27.48 | $4.2M | See Footnotes | 03/23/2023 |
03/24/2023 | DICE Therapeutics, Inc. | DICE | Purchase | Common Stock | 192.3k | $26.87 | $5.2M | See Footnotes | 03/23/2023 |
03/23/2023 | DICE Therapeutics, Inc. | DICE | Purchase | Common Stock | 155.1k | $26.67 | $4.1M | See Footnotes | 03/23/2023 |
02/23/2023 | Enliven Therapeutics, Inc. | IMRA | Grant | Common Stock | 1.2M | $0.00 | $0 | See Footnotes | 02/23/2023 |
01/20/2023 | Fulcrum Therapeutics, Inc. | FULC | Purchase | Common Stock | 1.9M | $13.00 | $25M | See Footnotes | 01/20/2023 |
01/06/2023 | Werewolf Therapeutics, Inc. | HOWL | Purchase | Common Stock | 1.9M | $2.21 | $4.1M | See Footnotes | 01/06/2023 |
01/04/2023 | Fulcrum Therapeutics, Inc. | FULC | Purchase | Common Stock | 122.3k | $7.03 | $859.7k | See Footnotes | 01/04/2023 |
01/04/2023 | Fulcrum Therapeutics, Inc. | FULC | Purchase | Common Stock | 58.4k | $7.80 | $455.1k | See Footnotes | 01/04/2023 |
01/03/2023 | Enliven Therapeutics, Inc. | IMRA | Purchase | Common Stock | 629.3k | $4.00 | $2.5M | See Footnotes | 01/03/2023 |
12/27/2022 | Fulcrum Therapeutics, Inc. | FULC | Purchase | Common Stock | 4.1k | $5.99 | $24.5k | See Footnotes | 12/27/2022 |
12/19/2022 | Fulcrum Therapeutics, Inc. | FULC | Purchase | Common Stock | 98.8k | $5.90 | $582.8k | See Footnotes | 12/19/2022 |
12/16/2022 | Fulcrum Therapeutics, Inc. | FULC | Purchase | Common Stock | 1.3M | $5.42 | $7.3M | See Footnotes | 12/14/2022 |
12/15/2022 | Fulcrum Therapeutics, Inc. | FULC | Purchase | Common Stock | 237k | $5.50 | $1.3M | See Footnotes | 12/14/2022 |
12/14/2022 | Fulcrum Therapeutics, Inc. | FULC | Purchase | Common Stock | 824.6k | $5.46 | $4.5M | See Footnotes | 12/14/2022 |
12/13/2022 | Solid Biosciences Inc. | SLDB | Grant | Director Stock Option (Right to Buy) | 9.6k | $6.47 | $62.4k | See footnotes | 12/13/2022 |
12/09/2022 | Enliven Therapeutics, Inc. | IMRA | Purchase | Common Stock | 19.3k | $3.93 | $75.8k | See Footnotes | 12/08/2022 |
12/09/2022 | Vor Biopharma Inc. | | Grant | Common Stock | 11.6M | $4.30 | $50M | See Footnotes | 12/09/2022 |
|